The research team, led by pharmacist Momoka Endo and colleagues, combed through every unplanned hospital admission recorded at their institution over a thirteen-month window, from March 2023 to March 2024. Out of 3,135 unplanned admissions in total, 343 involved patients who had recently received systemic anticancer therapy, and 161 of those—about 5.1 percent of all unplanned hospitalizations—were directly attributable to treatment-related adverse events. The median patient was 68 years old, and the cases spanned ages 5 to 92, underscoring how broadly cancer drug toxicity cuts across demographics. Laboratory values at admission told a story of physiologic stress: median serum albumin of 3.2 grams per deciliter, a marker of nutritional and inflammatory status, and a median C-reactive protein of 4.79 milligrams per deciliter, indicating substantial systemic inflammation.

What actually sent these patients to the hospital? Infections dominated the list. Non-pneumonic infections suggestive of treatment-related immunosuppression—enteritis, cholangitis, herpes zoster, and COVID-19 among them—accounted for 40 cases, or 24.8 percent of the total. Febrile neutropenia, the dangerous combination of fever and critically low white blood cell counts that oncologists dread, drove 23 admissions, or 14.3 percent. Fever and fatigue accounted for another 22 cases, pneumonia for 20, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea for 14. Nine admissions, 5.6 percent, stemmed from immune-related adverse events, the distinctive toxicities that arise when checkpoint inhibitors unleash the immune system against healthy tissue. Severity was graded using the Common Terminology Criteria for Adverse Events, version 5.0, the standard lexicon for oncology toxicity.

To determine how many of these admissions were avoidable, the investigators did something unusually rigorous for a retrospective chart review. Two pharmacists independently confirmed the causal link between each hospitalization and anticancer therapy, resolving disagreements by consensus. A multidisciplinary panel—two pharmacists, a physician, and a nurse—then re-examined each case, asking a deliberately constrained question: could the admission reasonably have been avoided through guideline-concordant interventions implemented before the adverse event began, using only the clinical information available at that time? The framework drew on domestic and international guidelines covering prophylactic granulocyte colony-stimulating factor, antiemetic therapy, antimicrobial prophylaxis, dose adjustment per package inserts, vaccination, and monitoring systems. A case was labeled potentially preventable if a recommended prophylactic intervention had been omitted, if treatment intensity had not been modified despite known risk factors, or if assessment was delayed after early symptoms appeared.

The verdict: 30 of the 161 cases, or 18.6 percent, were potentially preventable, with a 95 percent confidence interval of 13.4 to 25.4 percent. The largest share of missed opportunities—15 cases, half of all preventable admissions—involved optimization of supportive care. Seven patients needed better granulocyte colony-stimulating factor prophylaxis to ward off febrile neutropenia, three needed prophylactic antimicrobials, four needed intensified antiemetic regimens, and one needed better management of comorbidities. Six cases pointed to suboptimal anticancer therapy itself, where doses should have been reduced or modified based on patient characteristics. Another six involved failures of early detection—insufficient monitoring and patient education that might have caught deterioration before it required an ambulance. Five cases involved preventive measures that should have preceded treatment altogether, chiefly varicella-zoster vaccination.

Febrile neutropenia was the single most common event among the preventable admissions, appearing in 10 of the 30 cases, followed by gastrointestinal symptoms in 6. That pattern is clinically meaningful because febrile neutropenia is precisely the complication that prophylactic G-CSF is designed to prevent. International guidelines, including the American Society of Clinical Oncology recommendations cited by the authors, specify risk thresholds for primary and secondary prophylaxis, and real-world evidence from Japan has confirmed the effectiveness of pegfilgrastim in routine practice. When a hospitalization occurs because that well-established prophylaxis was never given, the gap is not scientific uncertainty—it is a systems failure in translating evidence into practice.

The antiemetic findings reveal a subtler problem. Standard prophylaxis was administered according to Japan Society of Clinical Oncology guidelines, yet in some patients, escalation based on nausea and vomiting experienced in prior treatment cycles was never implemented. Chemotherapy-induced nausea and vomiting is famously individual: some patients are inherently vulnerable, and a patient who vomited through cycle one is highly likely to vomit through cycle two unless the regimen is intensified. The authors point to emerging risk-stratification tools, such as those validated in the MyRisk trial, that could support individualized antiemetic strategies even in the first cycle. Similarly, while guidelines do not endorse universal antimicrobial prophylaxis, the study suggests that selected high-risk patients—those who are elderly, have a history of severe neutropenia, or carry multiple overlapping immunosuppressive factors—may merit risk-adapted prophylaxis that was not delivered.

Context matters for interpreting the 18.6 percent figure. Large administrative database studies in the United States have estimated that only about 5 to 7 percent of systemic anticancer therapy-related hospitalizations are potentially preventable, while detailed chart-review studies have suggested figures as high as 21 percent among patients with gastrointestinal malignancies. The Japanese study sits toward the higher end of that spectrum, likely reflecting the granularity of its method: administrative codes cannot capture a missing dose of prophylaxis or a delayed phone call, but a multidisciplinary team reading the full medical record can. The authors also note that most prior evidence comes from Western countries, and healthcare delivery systems in Asia may differ in ways that affect both the risk of unplanned admission and the opportunities to prevent it.

The study is candid about its limitations. It was single-center and retrospective, with a modest sample size, so institutional and regional factors may shape the results. Immune-related adverse events occurring more than 30 days after checkpoint inhibitor administration fell outside the observation window and were excluded. Preventability judgments, though structured and consensus-based, ultimately rest on retrospective clinical opinion; the team used a study-specific framework rather than a validated instrument, could not quantify inter-rater reliability, and did not prospectively test whether the identified interventions would actually prevent admissions. The remaining 131 cases were judged difficult to prevent, driven by disease progression, unpredictable serious toxicities, or adverse events that occurred despite appropriate supportive care—a reminder that cancer drug toxicity cannot be engineered away entirely.

Even with those caveats, the message is actionable and, in its way, optimistic. Nearly one in five treatment-related hospital admissions at this institution traced back to identifiable, correctable gaps: a prophylactic drug not given, a dose not adjusted for renal function or age, a worsening symptom not escalated, a vaccine not administered before immunosuppression began. The authors argue that standardized, regimen-specific supportive care protocols, systematic risk stratification, and team-based care models—incorporating electronic medical record alerts, pharmacist-led medication review, and nurse-led monitoring—could close many of these gaps. Structured follow-up for high-risk patients, including scheduled outpatient visits, telephone monitoring, and education that teaches patients when to call, may enable earlier intervention as symptoms worsen. As cancer care continues its migration into outpatient settings, where patients spend most of their treatment journey away from clinical oversight, the study suggests that the cheapest hospital bed is the one a patient never needs—and that a meaningful fraction of those beds can be freed with tools medicine already has.

Subject of Research: Preventability of unplanned hospitalizations due to adverse events in patients receiving systemic anticancer therapy

Article Title: Potentially preventable unplanned hospitalizations due to adverse events in patients receiving systemic anticancer therapy: a retrospective single-center study

Article References: Potentially preventable unplanned hospitalizations due to adverse events in patients receiving systemic anticancer therapy: a retrospective single-center study. (n.d.). https://doi.org/10.1007/s00520-026-11351-0

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11351-0

Keywords: systemic anticancer therapy, unplanned hospitalization, adverse events, febrile neutropenia, supportive care, G-CSF prophylaxis, antiemetic therapy, antimicrobial prophylaxis, vaccination, patient safety, oncology, pharmacists

The clinical stakes of the finding are considerable. Patients with EGFR-mutated non-small cell lung cancer typically respond well to third-generation EGFR inhibitors such as osimertinib, but resistance almost inevitably emerges, and once progression occurs on these targeted agents, treatment options narrow dramatically. Most patients in the Phase 1 study had already progressed on a third-generation EGFR inhibitor, and nearly two-thirds had also received platinum-based chemotherapy, meaning the antibody-drug conjugate was being tested in one of the most treatment-refractory settings in thoracic oncology. Against that backdrop, the observed activity offers a potential new direction for a population in which each successive line of therapy tends to yield shorter and less durable responses.

The design of the molecule itself reflects a deliberate strategic choice by its developers. Antibody-drug conjugates combine an antibody that homes in on specific proteins on the surface of cancer cells with a cytotoxic payload delivered through a chemical linker. By directing the drug to cells expressing EGFR or HER3, the therapy aims to concentrate its toxic cargo within tumor tissue while sparing healthy cells, at least relative to conventional chemotherapy. Targeting two receptors at once rather than one is intended to broaden coverage across heterogeneous tumors and to reduce the chance that cancer cells escape treatment by simply downregulating a single target. HER3 in particular has attracted attention because it is widely expressed in EGFR-mutated lung cancers and has been implicated in resistance to EGFR-targeted therapy.

Dose finding was a central objective of the study, and the results revealed a clear relationship between dose level and clinical activity, with responses becoming more frequent as the dose increased. At the dose ultimately selected for late-stage development, 2.5 milligrams per kilogram, the objective response rate reached 33.3 percent, and the confirmed objective response rate, which requires shrinkage to be verified on a subsequent scan, stood at 29.6 percent. Median progression-free survival, the average time patients lived before their disease began to grow again, was 6.9 months. For a cohort composed almost entirely of patients whose cancers had already outmaneuvered both a modern EGFR inhibitor and, in many cases, chemotherapy, those figures represent a clinically relevant level of benefit.

Safety has historically been the Achilles heel of therapies directed at EGFR and HER3, because both receptors are expressed to some degree in normal tissues, including the skin, gastrointestinal tract, and blood-forming system. Earlier experience with the investigational conjugate had raised concerns about hematologic toxicity, particularly declines in white blood cell counts that can leave patients vulnerable to infection. The study addressed this risk head-on by making primary prophylaxis with granulocyte colony-stimulating factor, a growth factor that stimulates white blood cell production, a mandatory part of the treatment protocol. This requirement was associated with an improved hematologic safety profile compared with what had been reported previously, demonstrating that thoughtful supportive care can meaningfully widen the therapeutic window of a potent targeted agent.

Beyond the blood counts, the overall tolerability data supported continued development. No deaths attributable to the treatment were observed across the study, and only a single patient discontinued therapy because of a treatment-related adverse event, an unusually low discontinuation rate for an oncology drug in this class. In practice, that means nearly all patients were able to remain on treatment and continue receiving whatever benefit the drug was providing, an important consideration when evaluating the real-world usefulness of a therapy intended for patients who have few remaining options.

The durability and breadth of the responses also carry scientific implications for how the field thinks about resistance to EGFR-targeted therapy. Resistance mechanisms after third-generation EGFR inhibitors are notoriously diverse, ranging from secondary mutations in EGFR itself to lineage shifts that transform the tumor’s behavior entirely. A therapeutic approach that does not depend on a single resistance mechanism, but instead exploits the persistent surface expression of EGFR and HER3 to deliver chemotherapy directly to tumor cells, offers a way to sidestep much of that heterogeneity. The results from the dose-expansion cohort suggest that this strategy can translate into measurable benefit even after multiple lines of prior treatment.

On the strength of these findings, the investigators have selected 2.5 milligrams per kilogram as the recommended Phase 3 dose and are advancing the regimen into IZABRIGHT-Lung01, a global registrational trial designed to test the therapy rigorously in patients with previously treated EGFR-mutated non-small cell lung cancer. Registrational studies of this kind are the decisive step between experimental development and potential regulatory approval, and their design will determine whether the signal seen in the Phase 1 cohort holds up under controlled comparison. Alexander Spira, M.D., of NEXT Oncology Virginia and Virginia Cancer Specialists in Fairfax, Virginia, said the findings support continued development of iza-bren and provide the rationale for advancing the 2.5 milligram per kilogram regimen into the global Phase 3 trial for this patient population.

For the broader lung cancer community, the study is a reminder of how quickly the treatment landscape evolves when rational drug design meets careful clinical optimization. Less than two decades ago, patients with EGFR-mutated lung cancer had no targeted options at all; today the challenge has shifted from initial sensitivity to overcoming resistance, and antibody-drug conjugates have emerged as one of the most promising tools for that second act. The Seoul presentation adds a candidate with dual-target specificity and a feasible safety profile to a competitive field, and the results of IZABRIGHT-Lung01 will determine whether patients whose disease has progressed on EGFR inhibitors gain a genuinely new standard of care. With incidence of lung cancer remaining among the highest of any malignancy worldwide, and with EGFR mutations representing a particularly common driver in Asian populations, the trial’s global scope underscores how consequential the answer may be for patients and clinicians on multiple continents.

The path from a Phase 1 dose-expansion cohort to a registrational program is never guaranteed, and the history of oncology drug development is littered with early signals that failed to confirm in larger, randomized settings. Nevertheless, the combination of objective responses in a heavily pretreated population, a median progression-free survival approaching seven months, no treatment-related deaths, and a supportive-care strategy that demonstrably improved tolerability gives this program a foundation that many earlier attempts at EGFR- and HER3-directed conjugates lacked. As the IZABRIGHT-Lung01 study begins enrolling patients worldwide, researchers and clinicians alike will be watching closely to see whether iza-bren can convert a promising Phase 1 signal into a new therapeutic option for one of the most pressing unmet needs in lung cancer medicine.

Subject of Research: A Phase 1 dose-expansion study of the investigational EGFR x HER3 antibody-drug conjugate iza-bren in previously treated EGFR-mutated non-small cell lung cancer.

Article Title: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer

Article References: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: EGFR-mutated lung cancer, HER3, antibody-drug conjugate, iza-bren, non-small cell lung cancer, EGFR inhibitor resistance, Phase 1 trial, IZABRIGHT-Lung01, objective response rate, progression-free survival, G-CSF prophylaxis, WCLC 2026